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Since the introduction of replacement
therapy in the early 1960s by the infusion
of plasma-derived factor VIII and IX prepa-
rations, important changes have occurred
for hemophilia patients. We studied the
medical and social developments over 30
years of hemophilia treatment. Since 1972,
5 cross-sectional national postal surveys
among all hemophilia patients in the Neth-
erlands were performed, the latest in 2001.
The prestructured questionnaires in-
cluded items on treatment, the presence
of inhibitory antibodies against factor VIII
or IX, the annual number of bleeding
episodes, use of inpatient hospital care,
and hepatitis C and HIV infections. Re-
sponse rate in 2001 was 70%. Young
patients (<16 years) with severe hemo-
philia showed the largest increase in use
of prophylaxis, from 34% in 1972 to 86%
in 2001. The occurrence of hemorrhages
has gradually decreased. Hospital admis-
sions decreased from 47% of all patients
in 1972 to 18% in 2001. Our study shows
that the treatment of patients with severe
hemophilia in the Netherlands has fo-
cused on the use of prophylactic treat-
ment, especially in children. This has
resulted in a decrease in bleeding fre-
quency and an improvement of the medi-
cal and social circumstances of patients.
(Blood. 2004;104:3494-3500)
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Introduction
Hemophilia is an X-linked genetic bleeding disorder caused by
deficiency of coagulation factor VIII (hemophilia A) or factor IX
(hemophilia B). Severe forms are characterized by major bleeding
after minor trauma. These hemorrhages often occur into joints,
eventually causing arthropathy, which is associated with physical
and psychosocial impairment.1
Since the introduction of replacement therapy in the early
1960s, the infusion of plasma-derived factor VIII and IX prepara-
tions, important changes have occurred for hemophilia patients.2,3
For patients with hemophilia, mean life expectancy has increased
over the years from less than 30 years in 1960 to an almost normal
life expectancy of 68 years in 1992.4,5 Prophylaxis was intro-
duced in the Netherlands in the late 1960s.6,7 As from the 1970s, it
became possible for patients to treat themselves at home and the
introduction of clotting factor concentrates in 1978 further facili-
tated developments. Although the general superiority of prophylac-
tic treatment over on-demand treatment has been demonstrated,6,8,9
the questions of when and in whom to start, and how to dose
prophylactic therapy, remain a subject of discussion.10 Some
believe that intensified on-demand treatment may be as effective as
prophylaxis. Arguments in favor of on-demand therapy include
fewer exposures with a potential concomitant reduction in patho-
gen exposure, less financial burden for the family (depending on
the health care system) and society, and greater therapeutic
maneuverability in times of reduced product availability.11 Random-
ized clinical trials to compare cost effectiveness of prophylaxis and
on-demand treatment are ongoing.12,13
Although treatment with clotting factor concentrate has enabled
patients to participate fully in normal life, the infusion of plasma
products has also had important adverse effects, such as infections
with human immunodeficiency virus (HIV) and hepatitis C virus
(HCV) and inhibitor development. Of the Dutch hemophilia
patients who were treated with plasma-derived clotting factors
before 1985, 17% became infected with HIV.2 Plasma-derived
products have been safe for hepatitis B and HIV since 1985, and
also for HCV patients since 1992.14
In 1995, recombinant factor VIII products were introduced in
the Netherlands and have become increasingly used,15 especially in
previously untreated patients; along with the use of purified
plasma-derived products, this minimizes the risk of transmission of
HIV or HCV.16 Today, the most important complication of clotting
factor treatment is the development of neutralizing antibodies
(inhibitors) against factor VIII or IX.17
In the Netherlands, a series of 5 national postal surveys18,19 have
been performed from 1972 onward. In this study we evaluated the
most important medical and social developments over the last 3
decades of hemophilia treatment.
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Patients, materials, and methods
Patients
A nationwide postal survey was conducted in the Netherlands in 2001,
following 4 previous surveys in 1972, 1978, 1985, and 1992.18,19 We
contacted patients who were listed with the Netherlands Hemophilia
Society and the hemophilia treatment centers and we updated mailing lists
from previous surveys. In April 2001, 1567 questionnaires were sent to all
known Dutch hemophilia patients, followed by 2 reminders. Response was
given for all questionnaires that were returned, irrespective of diagnosis (ie,
hemophilia or other bleeding disorders). Although some questionnaires
were completed by patients with other bleeding disorders or symptomatic
carriers, this report is restricted to men with hemophilia A or B. The severity
of hemophilia was classified according to residual percentage of factor VIII
or IX clotting activity: severe (0.01 IU mL), moderate (0.01-0.05 IU mL),
or mild (0.05-0.4 IU mL). The self-reported type and severity of
hemophilia were verified with data from the treatment centers. The parents
or caretakers completed the questionnaire if the patient was younger than
12 years.
The 5 prestructured questionnaires that were used between 1972 and
2001 included many items that were identical: treatment modalities, the
presence of inhibitors, the annual number of bleeding episodes, the use of
inpatient hospital care, absence from school or work, degree of joint
impairment, employment, and disability. The questionnaires differed on
topical issues (eg, home treatment in 1978 and AIDS in 1985). In the 2001
questionnaire, items on hepatitis C and type of product were added.
This study was approved by the Medical Ethical Committee of the
Leiden University Medical Center.
Data analyses
All analyses were stratified by the severity of hemophilia and often by age
category as well. As the clinical characteristics of hemophilia A and
hemophilia B do not differ, we present combined results for hemophilia A
and B. Data on the treatment modality, the number of bleeding episodes, the
use of hospital facilities, and absence from school or work referred to the
year that preceded the questionnaire surveys (2000). Children were defined
as patients younger than 16 years, adolescents as patients between 16 and
25 years, and adults as patients older than 25 years. The use of prophylaxis
refers to patients who received prophylaxis as their main treatment
modality, excluding patients who received a combination of on-demand
treatment and prophylaxis during risk periods. Absence from school was
calculated only for that part of the population that followed a full-time
education. Absence from work was calculated for patients aged 16 to 65
years who had a paid job (full-time or part-time). The inactivity ratio was
calculated as the ratio of inactivity in the study population and inactivity in
Dutch men. Patients that did not have a full-time or part-time paid job were
defined as inactive. Descriptive statistics for age, the use of hospital
facilities, absence from work, and employment were compared with
national figures for the general male population that were provided by the
Central Bureau of Statistics Netherlands StatLine databank.20 Self-reported
measures on joint impairment were obtained for a series of 16 joints: the
neck, the left and right shoulder, the back, the left and right elbow, the left
and right wrist, the left and right hand and fingers, the left and right hip, the
left and right knee, and the left and right ankle. The possible scores were 0
(no impairment), 1 (some impairment without daily problems), 2 (some
impairment with daily problems), and a maximum of 3 (severe impairment
with complete loss of function).
From scores of the 16 separate joints, a joint score was calculated with a
minimum score of 0 and a maximum score of 48 points. As joint
impairment was reported most frequently in the ankles, elbows, and knees,
these were analyzed separately.
Results
Response and patient characteristics
Response was 70% in 2001 compared with 84% in 1972,19 70% in
1978,21 81% in 1985,22 and 78% in 1992.18 One hundred ninety-
eight patients participated in all 5 surveys. Table 1 shows the
characteristics of participants in each of the 5 surveys. The mean
age of participants increased from 21 years (median, 19; range,
0-74 years) in 1972 to 35 years (median, 36; range, 0-90 years) in
2001. This was still somewhat lower than the mean age of Dutch
men, which increased from 32 to 37 years over the same period. Of
all participants in 2001, 39% had severe hemophilia, 17% had
moderate hemophilia, and 44% had mild hemophilia. In 23% of
patients, the genetic inheritance pattern of the disease was that of
isolated hemophilia: they had no other family members with
hemophilia. This proportion had remained constant over the 30
years spanned by the surveys. Thirty-eight percent of patients with
severe hemophilia were isolated patients, and 13% of patients with
moderate hemophilia were isolated patients.
Treatment
In 2001, 580 patients (54%) received treatment on-demand and 305
patients (29%) received prophylaxis, whereas 127 patients (12%)
were treated on-demand at times and prophylactically at other
times. For 54 patients (5%), no data were available about treatment,
and most of these patients (n  45) had mild hemophilia. Prophy-
lactic treatment was used mostly in children and adolescents with
severe hemophilia (Table 2). This group also showed the largest
increase in use of prophylaxis, from 34% and 31% in 1972 to 86%
and 90% in 2001; for adults with severe hemophilia this increased
from 14% in 1972 to 54% in 2001. A substantial proportion of adult
patients (15/39, 38%), who now were treated on-demand only, had
been treated prophylactically in the past.
The median age of starting prophylactic treatment was 2 years
in 2001 (range, 0-11 years) compared with 8 years (range, 0-15
years) in 1978 and 5 years (range, 1-15 years) in 1985. The
majority of patients on prophylaxis (64%; n  195) infused
Table 1. Overview of characteristics of participants in the Hemophilia in the Netherlands studies obtained from self- reported data
1972, N  447 1978, N  560 1985, N  935 1992, N  980 2001, N  1066
Median age, y (range) 19 (0-74) 23 (0-70) 28 (0-85) 31 (0-84) 36 (0-90)
Severity of hemophilia, no. of patients (%)
Severe, less than 0.01 IU mL 159 (36)* 245 (44) 384 (41) 387 (39) 420 (39)
Moderate, 0.01-0.05 IU mL 83 (19) 106 (19) 175 (19) 173 (18) 176 (17)
Mild, greater than 0.05-0.4 IU mL 172 (38) 138 (25) 376 (40) 420 (43) 470 (44)
Type A hemophilia, no. of patients (%)† 377 (84) 481 (86) 801 (86) 853 (87) 925 (87)
Sporadic hemophilia, no. of patients (%) 112 (25) 128 (23) 237 (25) 195 (20) 246 (23)
N indicates the entire population under study.
*Severity data was missing for 33 patients in 1972, and for 71 patients in 1970.
†All other patients are patients with hemophilia B.
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clotting factor concentrate themselves. The percentage of patients
on home treatment had increased from 4% in 1972 to 82% in 2001.
In 2001, 88% (n  269) of patients on prophylaxis were on
home treatment.
Patients who had been treated in the year preceding the survey
had used plasma-derived products (41%; n  300) and recombi-
nant factor VIII or IX products (48%; n  349) equally as often.
Among children younger than 16 years, a larger proportion solely
used a recombinant product (78%; n  155).
Outcome of treatment
Table 3 shows effects of treatment over 30 years. Of all patients
with severe hemophilia participating in 2001, 21% (n  88)
reported no hemorrhages in the previous year compared with 36%
(n  64) of patients with moderate hemophilia and 68% (n  319)
of patients with mild hemophilia. Since 1972, the annual median
number of symptomatic hemorrhages has gradually decreased from
20 (range, 0-98 symptomatic hemorrhages) in 1972 to 5 (range,
0-51 symptomatic hemorrhages) in 2001 in children with severe
hemophilia, whereas a similar trend was seen for patients with
moderate hemophilia. In patients with mild hemophilia, the overall
median number of hemorrhages was zero in all 5 surveys.
Hemorrhages were most frequent into joints. In 2001, patients with
severe hemophilia had on average 3 joint bleeds (range, 0-75 joint
bleeds) compared with 7 joint bleeds (range, 0-80 joint bleeds) in
1992. A substantial number of hemorrhages were traumatic,
especially in children (46% versus 16% in adult patients).
One or more hospital admissions during the year preceding the
survey decreased from 51% of patients with severe hemophilia in
1972 to 22% in 2001, which still clearly exceeded the rate of
hospitalization in the general Dutch male population, which was
5% in 2000. The median duration of stay in the hospital of patients
Table 2. Characteristics of treatment in patients with severe and moderate hemophilia given by age
1972 1978 1985 1992 2001
Severe hemophilia
Prophylaxis, proportion of patients (%)
Children, 0-16 y 22/65 (34) 41/91 (45) 69/111 (62) 64/92 (70) 112/130 (86)
Adolescents, 17-25 y 12/39 (31) 27/54 (50) 43/72 (60) — 38/42 (90)
Adults, older than 25 y 8/57 (14) 28/99 (28) 71/201 (35) 119/232 (51) 134/248 (54)
Median age at first prophylaxis, y (range) — 8 (0-15) 5 (1-15) — 2 (0-11)
Home treatment, no. of patients (%) 7 (4) 72 (29) 259 (67) 286 (74) 346 (82)
Moderate hemophilia
Prophylaxis, proportion of patients (%)
Children, 0-16 y 6/41 (15) 9/41 (22) 7/59 (12) 7/41 (17) 7/46 (15)
Adolescents, 17-25 y 4/14 (29) 7/26 (27) 1/19 (5) — 4/23 (17)
Adults, older than 25 y 1/27 (4) 4/39 (10) 10/97 (10) 11/98 (11) 10/107 (9)
Home treatment, no. of patients (%) 2 (2) 14 (13) 39 (22) 51 (30) 57 (32)
— indicates not available.
Table 3. Outcome of treatment presented for patients with severe hemophilia and moderate hemophilia
1972 1978 1985 1992 2001
Severe hemophilia, N 159 245 384 387 420
Hemorrhages, median no. per year (range)*
Children, 0-16 y 20 (0-98) 20 (0-70) 10 (0-65) 10 (0-98) 5 (0-51)
Adolescents, 17-25 y 20 (0-98) 17 (0-100) 10 (0-90) 10 (0-98) 6 (0-75)
Adult, older than 25 y 14 (0-97) 15 (0-100) 10 (0-90) 10 (0-82) 7 (0-75)
Hospital admissions*
Hemophilia, % 51 38 25 22 22
Dutch males, % — — 6 6 5
Duration of stay, median no. of d/patient (range) 28 (2-252) 20 (1-180) 11 (1-100) 5 (0-330) 7 (0-89)
Absenteeism due to hemophilia, d (range)*
School† 30 (0-80) 15 (0-80) 4 (0-80) 2,5 (0-80) 7 (0-90)
Work‡ 15 (0-80) 20 (0-213) 7 (0-319) 8 (0-330) 5 (0-365)
Moderate hemophilia 23 106 175 173 176
Hemorrhages, median no. per year (range)*
Children, 0-16 y 4 (0-40) 10 (0-104) 3 (0-66) 7 (33) 2 (0-57)
Adult, older than 25 y 4 (0-50) 5 (0-100) 2 (0-40) 3 (0-52) 1 (0-71)
Hospital admissions*
Admitted, % 51 27 23 22 15
Duration of stay, median no. of d/patient (range) 17 (2-180) 10 (1-50) 7 (1-50) 5 (0-72) 6 (0-31)
Absenteeism due to hemophilia, d (range)*
School† 30 (0-80) 5 (0-80) 3 (0-50) 0 (0-15) 5 (0-20)
Work‡ 2 (0-80) 13 (0-130) 7 (0-319) 5 (0-365) 3 (0-120)
N indicates the entire population under study.
*Reported for the year previous to the questionnaire.
†Due to hemophilia in patients following full-time day education.
‡Total absence in employed people between 15 and 64 years of age.
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with severe hemophilia decreased from 28 in 1972 to 7 days (range,
0-89 days) in 2001, which was similar to the figure for the general
Dutch male population. Seventy percent of the admissions were
directly related to hemophilia (eg, hemorrhage or orthopedic
surgery). Moderate and mild hemophilia also led to hospitalizations
in excess of the rate in the population: in both patient populations
15% had to be admitted in 2001. Orthopedic surgery was a frequent
indication for hospitalization, which occurred in 26% (n  107) of
patients with severe hemophilia, in 17% of patients with moderate
hemophilia, and in 13% of patients with mild hemophilia in a
5-year period preceding the survey. In patients with mild hemo-
philia, 50% of orthopedic surgery was related to hemophilia, for
patients with moderate and severe hemophilia this was 76% and
92%, respectively.
In 2001, absence from school was 7 days (range, 0-90 days)
among the 121 patients (29%) with severe hemophilia who
participated in full-time education, of which 4 days were due to
hemophilia; in patients with moderate hemophilia, this was 5 days,
of which 2 days were due to hemophilia. The median number of
days that patients with mild hemophilia were absent from school
was 3 days (range, 0-40 days), of which 1 day was due to
hemophilia. Absence from work for 157 patients with a paid job
(full-time or part-time) in 2001 was on average 5 days, ranging
from 0 days to a full year. Restricting to patients working full-time,
the median number of days absent from work was 3 (range, 0-242
days; mean, 10.7 days). Considering a total work year of 260 days,
absence from work was 4.1%. In the Dutch population, this ranges
from 5.5% (private companies) to 7.7% (civil service). In patients
with moderate hemophilia, this was 3 days (range, 0-36 days).
Restriction on the capacity to perform regular labor among patients
between 15 and 64 years of age with severe and moderate
hemophilia is shown in Table 4. Of the “inactive” patients, 69
patients (75%) were officially registered as fully or partially
disabled. Although the percentage of “inactive” patients decreased
compared with earlier surveys, the inactivity ratio remained
constant over the last decade. In 2001, 72% of patients with HIV
infection performed a full-time or part-time paid job compared
with 51% in 1992. The median age of inactive patients had
increased over the last 3 decades from 32 years (range, 16-60 years)
in 1972 to 49 years (range, 17-63 years) in 2001. Compared with
the Dutch male population, the unemployment rate was low: 2% in
patients versus 2.5% in the Dutch male population.
Joints
Severe joint impairment was most frequently reported for the
ankle, knee, and elbow joints by patients with severe and moderate
hemophilia (Table 5). None of the patients with mild hemophilia
reported severe joint impairment in any of these 6 main joints. The
overall proportion of patients with severe hemophilia reporting one
or more severely impaired joints did not change much over the
years: 31% in 1972 and 1992 and 34% in 2001 (Table 6). The same
was observed for the median joint score, which was 5 in 1972 and
in 2001. The percentage of patients reporting severe joint impair-
ment in the age category 0 to 16 years decreased since 1972.
Although no change was observed in the percentage of patients
with severe joint impairment in the age category 25 to 40 years, the
median joint score showed a decrease. In patients older than 40
years, an increase was seen between 1992 and 2001 in the
percentage of patients with severe joint impairment and the median
joint score.
For patients with moderate hemophilia, the median joint score
remained low over 30 years: 1 point in 1972 to 2 points in 2001
(Table 7). The percentage of patients reporting severe joint
impairment in at least one of the main joints slightly increased
between 1992 to 2001 from 14% to 18%. In patients with moderate
hemophilia older than 40 years, an increase in the percentage of
patients reporting severe joint impairment was observed. In the
2001 survey, 4 patients aged 0 to 16 years reported severe joint
damage: all were treated with prophylaxis but still reported a high
number of annual joint bleeds ranging from 3 to 10. No data were
available on the severity of these bleedings. None of these patients
reported the presence of inhibitory antibodies. In 2001, 43% of the
patients with severe hemophilia reporting severe joint impairment
had one joint with total loss of function; 6% (n  8) reported a total
loss of function in all 6 joints. The mean number of reported joints
with severe impairment did not change over the years (data
not shown).
Of all patients with severe hemophilia, 22% did not report
impairment of any of the main joints in 2001 compared with 19% in
1992 (Table 8). The absence of joint impairment was related to age,
as it was reported by 59% of patients aged 0 to 16 years, 17% of
those aged between 17 and 25 years, and 3% of patients with severe
hemophilia older than 40 years of age. In 3 decades the percentage
of patients that reported no joint damage in the age category 0 to 16
Table 4. Inactivity of patients aged 15 to 64 years with severe and moderate hemophilia who did not follow full daytime education compared
with Dutch males
1972, n  113 1978, n  168 1985, n  330 1992, n  352 2001, n  341
No. of inactive patients, median (%) 24 (21) 52 (31) 115 (35) 125 (36) 92 (27)*
Inactive Dutch males, % 9 15 23 27 23
Inactivity ratio† 2.3 2.1 1.5 1.3 1.2
Median age of inactive patients, (range) 32 (16-60) 36 (19-64) 41 (19-64) 42 (20-62) 49 (17-63)
N indicates the entire population under study.
*2  3.44; P  .05.
†The inactivity ratio was calculated as the ratio of inactivity in hemophilia patients and inactivity in Dutch males.
Table 5. Self-reported severe joint impairment in ankle, elbow, and
knee joints in patients with severe and moderate hemophilia
No. of impairments, (%)
Severity of hemophilia
Severe, less than
0.01 IU mL, N  420
Moderate,
0.01-0.05 IU mL, N  176
Ankle joints
Left 74 (18) 9 (5)
Right 76 (18) 10 (6)
Knee joints
Left 67 (16) 13 (7)
Right 69 (16) 17 (10)
Elbow joints
Left 34 (8) 5 (3)
Right 45 (11) 5 (3)
N indicates the entire population under study.
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years increased from 40% to 59%, and in the age category 17 to 25
years from 5% to 17%.
Side effects of treatment
The presence of neutralizing antibodies to factor VIII or IX
(inhibitors), either in the present or in the past, was reported by
13% (52/420) of patients with severe hemophilia (14%, or 51/388,
in 1992), by 7% of patients with moderate hemophilia, and by 5%
of patients with mild hemophilia (Table 9). Of these patients, 86
(96%) had hemophilia A.
In 2001, 29 patients (5%) treated before 1985 were HIV
positive, of which 25 patients were also infected with HCV. In
1992, 55 (8%) patients were HIV positive. In 2001, 344 patients
(44%) reported a current infection with HCV, whereas 97 patients
(13%) had been infected in the past but have cleared the virus
naturally or through treatment. As no specific items regarding this
subject were included in the questionnaire, we were not able to
make a distinction between these 2 ways of clearance.
Discussion
In this repeated cross-sectional study, we studied the medical and
social consequences of 3 decades of hemophilia treatment in the
Netherlands. We observed a steady decrease in the annual number
of hemorrhages, hospital admissions, duration of stay in hospital,
and days absent from school or work. Changes in treatment are
reflected by an increase in the use of prophylaxis, especially in
children. Despite intensified treatment, limited improvement was
observed in self-reported impairment of joint function in patients
older than 16 years. In the youngest patients, a slight improvement
was reported.
Our study offers a unique overview of the health status of
hemophilia patients over a prolonged period of time. No other
nationwide studies over such a long period of time are available.
The estimated prevalence of hemophilia at birth is 20.3 per 100 000
male inhabitants.23 With 7.91 million men in the Netherlands, the
Table 6. Self-reported impairment of the joints in patients with severe hemophilia
1972 1978 1985 1992 2001
Aged 0-16 y
Median joint score (range)* 1 (0-19) 1 (0-25) 1 (0-10) 0 (0-7) 0 (0-33)
Severe joint impairment, proportion of patients (%)† 7/65 (11) 8/92 (9) 4/111 (4) 1/92 (1) 4/130 (3)
Aged 17-25 y
Median joint score (range)* 5 (0-16) 4 (0-25) 3 (0-19) 3 (0-12) 3 (0-13)
Severe joint impairment, proportion of patients (%)† 9/39 (23) 12/54 (22) 11/84 (13) 12/64 (19) 8/42 (19)
Aged 25-40 y
Median joint score (range)* 10 (2-13) 9 (0-22) 8 (0-31) 7 (0-28) 5 (0-24)
Severe joint impairment, proportion of patients (%)† 22/39 (56) 21/69 (30) 41/115 (36) 42/119 (35) 30/89 (34)
Older than 40 y of age
Median joint score (range)* 12 (4-26) 11 (3-41) 12 (0-42) 12 (0-40) 15 (0-48)
Severe joint impairment, proportion of patients (%)† 11/16 (69) 16/30 (53) 44/74 (60) 63/113 (56) 102/159 (64)
Overall
Median joint score (range)* 5 (0-26) 5 (0-41) 5 (0-42) 6 (0-40) 5 (0-48)
Severe joint impairment, proportion of patients (%)† 49/159 (31) 57/245 (23) 100/384 (26) 118/388 (30) 144/420 (34)
Median joint score over 16 joints (min  0, max  48) and severe joint impairment in the left and right ankle, elbow, and knee joints.
*The median joint score was calculated as the median over the sum of the scores of 16 joints, which have been scored as follows: 0 indicates no impairment; 1, some
impairment; 2, some impairment with daily problems; and 3, severe impairment with total loss of function.
†Severe impairment with total loss of function reported in 1 or more of the 6 main joints.
Table 7. Self-reported impairment of the joints in patients with moderate hemophilia
1972 1978 1985 1992 2001
Aged 0-16 y
Median joint score* (range) 0 (0-10) 0 (0-6) 0 (0-14) 0 (0-8) 0 (0-7)
Severe joint impairment, proportion of patients (%)† 5/42 (12) 2/41 (5) 1/59 (2) — 1/46 (2)
Aged 17-25 y
Median joint score* (range) 2 (0-9) 1 (0-7) 1 (0-8) 1 (1-5) 1 (0-10)
Severe joint impairment, proportion of patients (%) 1/14 (7) — 1/22 (5) — 1/23 (4)
Aged 25-40 y
Median joint score* (range) 5 (0-27) 7 (0-17) 3 (0-20) 3 (0-12) 4 (0-16)
Severe joint impairment, proportion of patients (%) 2/18 (11) 6/24 (25) 10/58 (17) 8/45 (18) 6/35 (17)
Older than 40 y of age
Median joint score* (range) 4 (0-10) 3 (0-15) 5 (0-24) 6 (0-24) 5 (0-44)
Severe joint impairment, proportion of patients (%) 3/9 (33) 3/15 (20) 6/36 (17) 16/53 (30) 23/72 (32)
Overall
Median joint score* (range) 1 (0-27) 1 (0-17) 1 (0-24) 2 (0-24) 2 (0-44)
Severe joint impairment, proportion of patients (%) 11/83 (13) 11/95 (10) 18/157 (10) 24/173 (14) 31/176
Median joint score over 16 joints (min  0, max  48) and severe joint impairment in the left and right ankle, elbow and knee joints.
—indicates not present.
*The median joint score was calculated as the median over the sum of the scores of 16 joints, which have been scored as follows: 0 indicates no impairment; 1, some
impairment; 2, some impairment with daily problems; and 3, severe impairment with total loss of function.
†Severe impairment with total loss of function reported in one or more of the six main joints.
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estimated total number of hemophilia patients in the Netherlands is
1606. We reached 1567 patients with hemophilia and 70% partici-
pated in our study. As the nonresponders appeared not to differ
from the responding patients in severity and type of hemophilia and
were only slightly younger (33 vs 36 years), we feel confident to
generalize our findings to the total population of hemophilia
patients in the Netherlands.
Self-reported data may be less objective compared with medical
records or laboratory data but offer an important insight in the view
of patients of their own situation. Because patients with hemo-
philia, especially patients with severe hemophilia, are confronted
with their disease on a daily basis and are well informed about their
disease, we assume data on treatment and side effects of treatment
are trustworthy. To rule out error in information on type and
severity of hemophilia, we contacted the treating physicians.
Between 1972 and 2001, the number of patients participating in
the Hemophilia in the Netherlands project has doubled, which may
be explained by the growth of the Dutch population and the
registration of patients with hemophilia in treatment centers.
Previously, patients with severe hemophilia could be treated in
hospitals all over the country. Since 2001, all patients with
hemophilia need to be registered in one of the treatment centers.
Hemophilia treatment has intensified over the last 3 decades.
We observed a marked increase in the use of prophylactic treatment
in children, whereas in adults this was less pronounced. In 2001,
85% of all children with severe hemophilia and over half of the
adult patients with severe hemophilia received prophylactic treat-
ment. This increase is likely to have contributed to the decrease of
the annual number of total hemorrhages. If only joint bleeds were
taken into consideration, a lower number was observed in 2001
compared with 1992, which is in line with the findings of a
single-center study.8 Although evolution to a more intense treat-
ment regimen has resulted in a decrease of hospitalization, the
percentage of patients with hemophilia annually admitted to
hospital has still increased 3-fold compared with the Dutch male
population. However, the number of days spent in hospital has
decreased substantially from 28 to 7 days and is now equal to the
mean duration of stay in hospital for all who are admitted. In our
population, hospital admission occurred frequently in patients with
mild and moderate hemophilia, which can be explained by the
policy to admit patients with hemophilia for small operations or for
observation after falls.
As we also observed in the 1991 survey, there was no further
improvement in perceived joint impairment compared with the
earlier surveys covering the period 1972 to 1985. A previous study
presenting joint pathology by radiologic assessments showed a
clear improvement of the joint scores over the same period.8 It may
well be that perceived joint impairment did not further improve due
to different appreciations of signs and symptoms over time.
Remarkably, even among patients younger than 25 years with
severe hemophilia, 7% reported at least one joint with complete
loss of function in the latest survey. The discrepancy between
radiologic assessments and our findings will be the subject of future
study. Some patients with moderate hemophilia reported severe
joint impairment. Although our measure for joint impairment was
self-reported and subjective, we may conclude from this that the
goal of prophylactic therapy, which is aimed at a trough level of
1%, may not be ambitious enough.
We observed a cumulative incidence of inhibitors of 13% in
patients with severe hemophilia, which is similar to other studies of
previously treated patients.24 Since 1985 this figure has stayed
constant. The prevalence of HIV seropositivity has declined
further, due to deaths and an increasing number of patients born
after plasma products became safe. The positive effects of highly
active antiretroviral therapy (HAART) in 1996 for HIV-positive
patients were observed through an improvement of participa-
tion in labor since 1992. About 40% of hemophilia patients
treated with plasma-derived products before 1992 were infected
with HCV.
The number of days patients were absent from school or work
due to hemophilia has decreased over the years. Similar figures for
absence from work were shown by Szucs et al25 in 1998.
Remarkably, the percentage of absence from work in men with
severe hemophilia working full-time was lower than in the Dutch
male population in 2001. An improvement is also seen through a
decrease in the percentage of inactive patients since 1992. This is in
line with the Dutch male population. The inactivity ratio has
Table 8. Absence of joint impairment in patients with severe hemophilia in the left and right ankles, elbows, and knees
1972 1978 1985 1992 2001
Severe hemophilia, no. of patients (%)
Aged 0-16 y 26 (40) 40 (44) 53 (48) 56 (61) 76 (59)
Aged 17-25 y 2 (5) 5 (9) 7 (8) 9 (14) 7 (17)
Aged 25-40 y — 2 (3) 3 (3) 2 (2) 7 (8)
Older than 40 y of age — — 3 (4) 1 (1) 4 (3)
Overall 28 (18) 47 (19) 66 (17) 74 (19) 94 (22)
Moderate hemophilia, no. of patients (%)
Aged 0-16 y 23 (55) 28 (68) 42 (71) 29 (71) 37 (80)
Aged 17-25 y 5 (36) 13 (50) 9 (41) 17 (50) 11 (48)
Aged 25-40 y 2 (11) 3 (13) 14 (24) 14 (31) 13 (37)
Older than 40 y of age 3 (33) 5 (33) 11 (31) 15 (28) 17 (24)
—indicates not present.
Table 9. Complications of hemophilia treatment
1972 1978 1985 1992 2001
Inhibitory antibodies*
Cumulative incidence, proportion
of patients 31/384 51/388 52/420
Current inhibitors, no. of patients (%) — — 19 (5) 29 (7) 15 (4)
Past inhibitors, no. of patients (%) — — 12 (3) 22 (6) 37 (9)
HIV infection, no. of patients (%)† — — 36 (4) 55 (8) 29 (5)
Hepatitis C, no. of patients (%)‡
Current infection — — — — 344 (45)
Past infection — — — — 97 (13)
—indicates no data available.
*Reported for patients with severe hemophilia.
†Reported for patients treated with clotting factor before 1985.
‡Reported for patients treated with clotting factor before 1992.
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become close to 1, from which we can conclude that patients with
severe and moderate hemophilia participate as actively in the
workforce as other men. These developments show that although a
large number of adult patients are limited in daily activities due to
joint problems or viral infections, hemophilia has nowadays only a
minimal influence on social participation.
It should be taken into consideration that the focus on the use of
prophylactic treatment in the Netherlands has lead to a 260%
increased annual clotting factor consumption over the last 3
decades. Mean clotting factor consumption for both patients on
prophylaxis and on-demand treatment increased from 610 IU kg1
year1 in the 1970s to 1578 IU kg1 year1 in the 1990s.8 Clotting
products have not become cheaper, which implies a larger increase
in costs, which, however, has been accompanied by direct and
indirect gains (eg, a decrease in absence from work and increased
employment rates).
In conclusion, our study shows that the treatment of patients
with severe hemophilia in the Netherlands has focused on the use
of prophylactic treatment, especially in children. This has re-
sulted in an improvement of the medical and social situation of
patients. Although the current situation of Dutch hemophilia
patients proves to be good, more improvements are possible. A
remarkable finding was that the prevalence of perceived joint
impairments among young patients did not show the decrease
we had expected.
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